0001209191-21-052394.txt : 20210818
0001209191-21-052394.hdr.sgml : 20210818
20210818190353
ACCESSION NUMBER: 0001209191-21-052394
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210816
FILED AS OF DATE: 20210818
DATE AS OF CHANGE: 20210818
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Garland J. Scott
CENTRAL INDEX KEY: 0001533228
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40431
FILM NUMBER: 211187889
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001845337
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832415215
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 395 OYSTER POINT BLVD STE 217
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080-1930
BUSINESS PHONE: 206-913-4300
MAIL ADDRESS:
STREET 1: 395 OYSTER POINT BLVD STE 217
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080-1930
FORMER COMPANY:
FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC
DATE OF NAME CHANGE: 20210209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-16
0
0001845337
Day One Biopharmaceuticals, Inc.
DAWN
0001533228
Garland J. Scott
395 OYSTER POINT BLVD, SUITE 217
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Stock Option (Right to buy Common Stock)
24.65
2021-08-16
4
A
0
48072
0.00
A
2031-08-15
Common Stock
48072
48072
D
The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on August 16, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Charles N. York II, as Attorney-in-Fact for Reporting Person
2021-08-18
EX-24.4_1004804
2
poa.txt
POA DOCUMENT
LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS
KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints Jeremy Bender and Charles N. York II, and each of them, a true and
lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity
as a representative of Day One Biopharmaceuticals, Inc. (the "Company"), any and
all Form 3, 4 or 5 reports required to be filed by the undersigned in accordance
with Section 16(a) of the Securities Exchange Act of 1934, as amended ("Exchange
Act"), and the rules thereunder with respect to transactions in securities of
the Company;
(2) do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5
report and timely file such report with the U.S. Securities and Exchange
Commission and any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney in-fact on behalf of the
undersigned, pursuant to this Power of Attorney, shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in
her/his discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform each and every act and thing whatsoever requisite,
necessary and proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or her/his
substitute or substitutes, shall lawfully do or cause to be done by virtue of
this Power of Attorney and the rights and powers herein granted. The
undersigned acknowledges that no such attorney in-fact, in serving in such
capacity at the request of the undersigned, is hereby assuming, nor is the
Company hereby assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Form 3, 4 or 5 reports with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of August 3, 2021.
/s/ J. Scott Garland
J. Scott Garland